Tag: Methylsulfonyl benzoxazine ampakine

  • CX-717

    Methylsulfonyl benzoxazine ampakine

    A methylsulfonyl benzoxazine ampakine that advanced furthest of the CX-series in human trials, including military sleep deprivation studies.

    Abstract

    CX-717 (1-(N-methyl-N-methylsulfonyl-aminobenzoyl)pyrrolidine; CAS 412960-03-7) is a methylsulfonyl benzoxazine ampakine developed at Cortex Pharmaceuticals that advanced further in human trials than other CX-series compounds. The compound was studied by DARPA and the Department of Defense for cognitive performance maintenance during sleep deprivation in military personnel; published results showed modest but reproducible improvements in vigilance and working memory performance during 24- to 72-hour sleep deprivation. CX-717 was also studied for adult ADHD with partial Phase 2 results. The compound did not advance to FDA approval. Pharmacokinetics: plasma half-life approximately 3 to 4 hours; oral bioavailability adequate. The compound is sold as a research chemical with limited availability.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.